Kornimate/medical-research-clean huggingface dataset:
myocardial fibrosis, function and aging

Conditions: Healthy

Summary: in normal ageing, the impact of myocardial fibrosis on myocardial function is unclear as diastolic function is reported to change according to age. the objective is to explore the relationship between myocardial function changes, with local (t1 and diffusion) fibrosis measures with magnetic resonance imaging (mri) as well as global measures of fibrosis (skin auto-fluorescence and collagen blood-biomarkers).


Eligibility criteria:
inclusion criteria: * physical activity ≤ 3 x(30') per week * no history of smoking, diabetes, myocardial infarction, heart failure, hypertension (\<140 or \<90 mmhg) and no anti-hypertensive or cardiovascular-related medications * no familial history of early myocardial ischemia * body mass index (bmi) \<30kg/m2 * normal routine lipid blood analysis * glycemia \<1.26g/l * normal electrocardiogram (ecg) exclusion criteria: * arrhythmia * hepatic insufficiency * pregnancy * claustrophobia * mri contrast allergy, * general contraindications to mri such as pacemaker, etc.

Keywords: myocardial fibrosis cardiac function ageing
radiofrequency ablation of pulmonary tumors response evaluation

Conditions: Non Small Cell Lung Cancer; Pulmonary Metastases

Summary: the study hypothesis is that the radiofrequency (rf) ablation is a safe and effective treatment for malignant lung tumors.

image-guided rf ablation is accepted as a viable therapeutic choice for patients with early-stage hepatocellular carcinoma or limited hepatic metastatic disease from colorectal cancer, when surgery is precluded (1, 2). recently, rf ablation has been proposed as a viable option for the treatment of pulmonary malignancies. experimental studies in animal tumor models have confirmed the effectiveness of rf ablation in the destruction of experimentally-induced pulmonary malignancies (3). pilot clinical investigations have suggested that the treatment can achieve high proportions of tumor response (4, 5). we designed a prospective, intention-to-treat, multicenter clinical trial aimed at assessing feasibility, safety and effectiveness of rf ablation in the treatment of lung malignancies.

Eligibility criteria:
inclusion criteria: 1. adult (\> 18 years) male or female patient 2. patient has biopsy-proven nsclc or lung metastasis 3. patient has been rejected for surgery and has been considered unfit for radiation therapy or chemotherapy 4. patient has as many as 3 tumors per lung, each 3.5 cm or smaller in greatest diameter, by ct scan 5. tumors are located at least 1 cm from trachea; main bronchi; esophagus; aorta; aortic arch branches; pulmonary artery; and heart 6. tumors are accessible by percutaneous route 7. patient has eastern cooperative oncology group (ecog) performance status of 0, 1, or 2 8. patient has platelet count \> 100 x 109 /l and international normalized ratio ≤ 1.5 9. patient has signed written informed consent prior to any study specific procedures. exclusion criteria: 1. patient has undergone previous pneumonectomy 2. patient is considered at high-risk for rf ablation due to major co-morbid medical conditions 3. patient has more than 3 tumors / lung 4. patient has at least one tumor \> 3.5 in greatest diameter 5. tumor is associated with atelectasis or obstructive pneumonitis 6. patient has renal failure requiring hemodialysis or peritoneal dialysis 7. patient has active clinically serious infection 8. patient has history of organ allograft 9. patient has history of substance abuse or any medical, psychological or social conditions that may interfere with his / her participation in the study or evaluation of the study results 10. patient is pregnant or breast-feeding 11. patient has ecog performance status \> 2 12. patient has platelet count ≤ 100 x 109 /l or international normalized ratio \> 1.5.

Keywords: non small cell lung cancer pulmonary metastases radiofrequency ablation
effects of an urban-gardening nutrition intervention for food insecure college students

Conditions: Food Insecurity; Obesity Prevention

Summary: the goal of this clinical trial is to learn if an urban gardening nutrition education program can have positive health effects on food insecure college students. the main question it aims to answer is to determine whether an 8-week urban-gardening nutrition intervention can improve fruit and vegetable intake, nutrition knowledge, body mass index (bmi) and body fat percentage in college students with food insecurity. participants will: fill out a questionnaire regarding demographics, food insecurity, fruit and vegetable intake, nutrition knowledge, self-efficacy and health beliefs. allow researchers to measure height, weight and body fat percentage participate in a 1-hour education cooking or gardening session once a week for 8 weeks receive text message reminders for meeting dates


Eligibility criteria:
inclusion criteria: * must be enrolled at fiu * age 18+ years old * literate in english * food insecure exclusion criteria: * students who are student athletes * women who are pregnant or planning to become pregnant in the next 6 months

Keywords: college student food insecurity gardening nutrition intervention college students nutrition education social cognitive theory
piloting a biofeedback intervention for adolescents with overweight and a history of adverse childhood experiences

Conditions: Obesity, Adolescent

Summary: adverse childhood experiences (aces), referring to traumatic experiences occurring before 18 years of age (e.g., abuse/neglect), are associated with a 30-70% increased risk of developing adolescent and adult obesity and obesity-related cardiometabolic comorbidities, which may be due to dysregulation in stress-related physiology and engagement in stress-related behaviors. while adolescents with aces have a 2.25 times increased risk of obesity, standard-of-care lifestyle (e.g., nutrition/physical activity) interventions do not typically incorporate trauma-informed care, including assessment and therapeutic attention to effects of aces. heart rate variability (hrv) biofeedback is an evidence-based, relatively brief, mind-body intervention targeting the stress physiology that can be dysregulated in adolescents with aces. the objective of this proposal is to adapt and test a 4-session hrv biofeedback protocol for 12-17-year-olds with bmi\>85th percentile and aces. first (phase 1), we will iteratively adapt a 4-session hrv biofeedback facilitator protocol with n=3-5 adolescents with overweight/obesity and aces, using adolescent quantitative and qualitative feedback to hone and optimize hrv biofeedback for this population (aim 1). next (phase 2), we will conduct a randomized waitlist-controlled pilot study of n=30 adolescents with overweight/obesity and aces to assess acceptability and feasibility (aim 2) and to describe changes in theorized targets of biofeedback (aim 3).


Eligibility criteria:
inclusion criteria: * four or more aces * bmi at or above the 85th percentile; exclusion criteria: * major renal, hepatic, endocrinologic, rheumatologic, cardiac, or pulmonary medical problem likely to affect mood or weight * medications affecting mood or weight (e.g. anti-anxiety/depressants/psychotics, stimulants, mood stabilizers, insulin sensitizers, weight loss)
pamiparib for consolidation treatment of unprogressed ls-sclc after concurrent chemoradiotherapy

Conditions: Limited Stage Small Cell Lung Cancer

Summary: this study is a prospective, single-arm, phase ii clinical trial, with 1-year pfs as the endpoint, to evaluate the efficacy and associated toxicity of pamiparib as single-agent consolidation treatment in patients with limited-stage small cell lung cancer(ls-sclc) patients who have not progressed following platinum-based concurrent chemoradiotherapy(ccrt) .


Eligibility criteria:
inclusion criteria: * the patient or a legally authorized representative must provide study-specific informed consent prior to study entry, had good compliance and cooperated with the follow-up. * age at least 18 years * pathologically (histologically or cytologically) proven diagnosis of limited stage small cell lung cancer (stage tx, t1-t4, n0-3, m0, american joint committee on cancer \[ajcc\] staging, 8th edition \[ed.\]), within 60 days prior to registration * patients must have had measurable disease (per response evaluation criteria in solid tumors \[recist\], version 1.1) prior to the required cycle of ccrt * patients must be free of disease progression and not be able to receive other antitumor therapy within 6 weeks of completion of ccrt * patients must submit archived or freshly biopsied tumor tissue (formalin-fixed, paraffin-embedded tissue block or approximately 15 unstained sections \[must have \>8 sections\]) along with the relevant pathology report. * eastern cooperative oncology group (ecog) performance status of 0-2 within 30 days prior to registration * patient life expectancy must be \>12 weeks exclusion criteria: * mixed sclc or nsclc confirmed by histology * previous tumor resection for ls-sclc * any patient treatable by surgery or stereotactic body radiation therapy/stereotactic ablative radiation therapy should be excluded * expected to receive any other form of anti-tumor therapy during the study period * previous treatment with parp inhibitor drugs * any active malignancy within 2 years prior to enrollment, excluding the specific cancers being studied in this study and locally recurrent cancers that have been cured (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, cervical cancer carcinoma in situ or carcinoma in situ of the breast) * women who are pregnant, breastfeeding, or planning to become pregnant during the study * concurrent participation in another therapeutic clinical trial
akathisia in post operative outpatients surgery

Conditions: Akathisia

Summary: the main objective of this study is to evaluate the incidence of akathisia with droperidol, the prophylactic treatment of post operative nausea and vomiting, used at two different doses, versus control group (ondansetron), in outpatient surgery.the primary endpoint is to compare the number of observed akathisia (barnes score \> 1) in the droperidol arms (0,625 mg and 1,25 mg) versus ondansetron 4 hours after recovery from anesthesia.the assumption is that there is a greater risk of akathisia among patients taking droperidol in prevention of npvo, that among patients taking ondansetron.


Eligibility criteria:
inclusion criteria: * patient over 18 and under 65 year-old * having a moderate to severe povn (post operative vomiting and nausea) risk, meaning with at least two risk factors in the simplified apfel score * outpatient surgery associated to a general anesthesia * patient having signed an informed consent- patient having a social protection exclusion criteria: * contraindication to droperidol * contraindication to ondansetron * patients usually treated with benzodiazepine or having been treated with benzodiazepine within 2 days prior to anesthesia * psychiatric and neurodegenerative diseases * severe anxiety * contraindication to general anesthesia or one of its components * allergy to propofol * inability to get informed (patient in an emergency situation, difficulties to understand) * patient under judicial protection * patient under tutorship or curatorship * pregnancy reported by the patient- breastfeeding * patient in an exclusion period
conservative versus surgical treatment of impacted femoral neck fracture in patient 75 years old and older

Conditions: Femoral Neck Fractures

Summary: the purpose of the study is to evaluate the safety and effectiveness of conservative treatment in treatment of patients over 75 years with impacted femoral neck fracture.

the study is to compare clinical outcomes between conservative treatment, internal fixation, and hemiarthroplasty in patients over 75 years with impacted femoral neck fracture. all the 3 groups were evaluated by hip pain(visual analogue scale,vas), hip function(harris hip score,hhs), health related quality of life(european quality of life-5 dimensions index scores, eq-5d). all thses parameters were assessed at admission and 1-, 3-, 6- 12-, 24- and 36 months after intervention. operation duration and blood loss were recorded. mortality, union rate, complications and re-operation were also monitored throughout the study.

Eligibility criteria:
inclusion criteria: patients \>75 years old who were diagnosed with impacted femoral neck fracture with confirmation of mutual embedding and close combination of the fracture ends by ct or mri scanning(including garden 1 and 2 and varus impacted fnf) were eligible for the inclusion. exclusion criteria: patients \<75 years old, pathological fracture, nonimpacted or displaced fracture, unable to walk previously, avascular necrosis of femoral head, previous symptomatic hip pathology (such as arthritis), infection, a history of fracture in the studied hip, deformity of lower limb.
role of microparticles in covid-19 infection

Conditions: COVID-19

Summary: among the distinctive features of covid-19, numerous reports have stressed the importance of vascular damages associated with coagulopathy onset. microparticles (mps) shed by apoptotic/stimulated cells are reliable markers of vascular damage released upon pro-inflammatory conditions and behave as active participants in the early steps of clot formation. in addition, mps carry ace1 and ace2, the cell-entry receptor for sars-cov2 in the vasculature and up-regulate ace1 expression in neighbouring endothelial cells. this may contribute to unopposed angiotensin ii accumulation which further exacerbate tissue injury and promote both inflammation and thrombosis. the aim of the study is to evaluate the impact of circulating mps on ace2 expression, the cell-entry receptor for sars-cov2 on endothelial cells.

circulating mps will be isolated from covid-19 patients with lupus anticoagulant, from coronary artery diseases patients and from healthy volunteers without cardiovascular risk factors. quantification of mps will be realized by prothrombinase assay. primary endothelial cells (ecs) from porcine coronary artery or porcine pulmonary artery will be isolated and cultured. ecs will be exposed to circulating mps. phenotypical changes (ace2 expression, cytoadhesins, cytokines, tissue factor expression) of ecs will be examined. susceptibility of ecs to sars-cov-2 infection will be determined.

Eligibility criteria:
inclusion criteria: * covid-19 patients: age \> 18 yr * sars-cov-2 infection within 12 months and positive lupus anticoagulant * patients with cardiovascular risk factors: at least among * hypertension, dyslipidemia, diabetes mellitus, obesity, smoker, healthy volunteers exclusion criteria: * significant comorbidities (active cancer, auto-immune diseases...)

Keywords: microparticles microvesicles vessel vasculature endothelium coagulation thrombosis
a trial to study how the body fights off cytomegalovirus (cmv) in hematopoietic transplant recipients.

Conditions: Cytomegalovirus Infection

Summary: this study is being done to determine how the body fights off a common virus known as cytomegalovirus (cmv). cmv is a virus that commonly infects humans and causes disease in patients with compromised immune function such as those who receive organ and tissue transplant. by knowing how the human body responds to the infection, researchers will be able to develop better methods on how to prevent this infection.

this study is looking at the cmv virus in hematopoietic stem cell donors and recipients. in the donor population, the study is looking at the participants blood to see if they contain cells that are active against the virus. information about the donor will be obtained through an interview and through review of medical records. a blood sample will be drawn at the time of the donor's evaluation, which will take place in conjunction with the regular blood tests that are ordered. participants of the study who are donors will only be involved in the study at the time of blood collection. participants who will be receiving hematopoietic stem cell transplantation will have data collected through an interview and review of medical records. participants will have blood drawn prior to transplant, weekly for 12 weeks and then monthly for three months following transplant. in addition, if cmv disease develops during this period of time, blood will be drawn till the participant is cured for the disease. all blood draws for thes study will take place in conjunction with the regular routine blood work. participants will be in the study for one year after transplant.

Eligibility criteria:
participants who will be undergoing blood marrow or stem cell transplant and donors that are 18 years of age or older, may be eligible to participate in this study.
effect of iron fortified wheat flour on cognition and iron status in indian school children

Conditions: Iron Deficiency; Iron Deficiency Anemia; Cognition

Summary: this study is designed to evaluate the efficacy of nafeedta-fortified whole wheat flour in improving cognition, hemoglobin, iron status and total body iron among school children in urban bangalore.

background: iron (fe) deficiency is a major cause of anemia in children. fortification of wheat flour with nafeedta, a highly bioavailable iron fortificant that protects fe from the phytic acid present in wheat flour, could be a practical approach to addressing this problem. aims: to evaluate the efficacy of nafeedta-fortified whole wheat flour in improving mental performance and reducing iron deficiency and improving body iron stores in urban, school going indian children. methods: a randomized, double-blind, 7 month, school-based feeding trial was carried out in bangalore, india. iron-depleted (serum ferritin, sf \ 7.6 mg/l), 6 -13 year old children (n=194) were randomly assigned to either receive a whole wheat flour based lunch meal fortified with 6 mg fe as nafeedta or an identical unfortified control meal. the meals were administered under supervision and left overs were weighed. hemoglobin (hb) and iron status were measured at baseline, 3.5 months, and 7 months. at baseline and at 7 months, the study children were also subjected to a battery of cognitive tests to assess attention/concentration, motor development, visuospatial and verbal abilities. sensory evaluation using triangle tests were carried out using meals prepared from the fortified and unfortified whole wheat flour.

Eligibility criteria:
inclusion criteria: * children with depleted iron stores (serum ferritin \ 7.6 mg/l) exclusion criteria: * hb \< 8g/dl, any metabolic illness, use of medication, on iron supplementation

Keywords: food fortification iron deficiency nafeedta iron deficiency anemia cognition
exploring different dose-frequency home photodynamic therapy protocols using a novel home-targeted led device for onychomycosis, a randomized feasibility trial.

Conditions: Onychomycosis of Toenails; Onychomycosis of Fingernail

Summary: this randomized feasibility trial aims to determine the optimal light energy dose and treatment frequency for home-based photodynamic therapy (hpdt) using a novel led device (l-home phod) for the treatment of onychomycosis.


Eligibility criteria:
inclusion criteria: patients diagnosed with onychomycosis (nail fungal infection) by a dermatologist. diagnosis criteria include at least one clinical criterion combined with at least one laboratory examination criterion. 2.1. clinical criteria: 2.1.1. discoloration patches/streaks on the nail. 2.1.2. onycholysis (nail separation from the nail bed). 2.1.3. subungual hyperkeratosis/debris (thickening under the nail). 2.1.4. nail plate thickening. 2.2. laboratory examination criteria: 2.2.1. direct microscopy using koh preparation. 2.2.2. histopathological examination using periodic acid schiff (pas) stain. 3. patients with distal lateral subungual onychomycosis (dlso) of the fingernails or toenails, except for the little toenail. 4. patients with onychomycosis who have limitations on or refuse oral antifungal treatment. 5. individuals willing to participate in the research after receiving a full explanation of the research details, able to comply with the research procedures, and have signed the informed consent form. exclusion criteria: participants will be excluded if they meet any of the following conditions: presence of nail abnormalities caused by other diseases or conditions. pregnant or breastfeeding. history of receiving oral antifungal agents within the past 6 months or topical antifungal agents within the past 1 month prior to enrollment. history of photosensitivity or photodermatitis. known allergy to methylene blue. presence of erythematous or edematous inflammatory skin conditions near the site of onychomycosis. severe peripheral arterial disease. uncontrolled diabetes mellitus or hba1c \> 8%. immunocompromised status, such as hiv infection with cd4 count \< 200 cells/mm³ or diagnosis of acquired immunodeficiency syndrome (aids). current use of immunosuppressive medications, including tacrolimus, azathioprine, cyclosporine, mycophenolate mofetil, or prednisolone \>10 mg/day.

Keywords: onychomycosis photodynamic therapy methylene blue home phototherapy portable device
safety study of bevacizumab plus chemotherapy to treat metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: to assess the safety profile of bevacizumab in combination with chemotherapy for the treatment of metastatic colorectal cancer

this is a multi-centre, observational, non-interventional study. patients with metastatic colorectal cancer eligible for bevacizumab in combination with chemotherapy treatment will be enrolled in this trial.

Eligibility criteria:
inclusion criteria: * with histologically confirmed metastatic colorectal cancer * patients with metastatic colorectal cancer who are eligible for bevacizumab in combination with chemotherapy treatment * written informed consent * unlimited line of treatment (first-line or second line is not limited) exclusion criteria: patients who are not eligible for bevacizumab treatment according to locally approved bevacizumab china package insert will be excluded. the following patients are not eligible for bevacizumab treatment according to local bevacizumab china package insert: * recent history of serious hemorrhage or hemoptysis of ≥1/2 teaspoon of red blood * proteinuria at baseline: patients discovered to have ≥ 2 grams of proteinuria/24 hours \* * the measurement of 24-hour proteinuria level is recommended for patients with moderate to high proteinuria risk indicated by clinical judgement. the treatment with bevacizumab should be delayed when proteinuria is ≥2g/24 hours. * major surgical procedure within 28 days prior to treatment initiation, or not fully healed wounds * pregnant or lactating women * excluding patients known to be allergic to bevacizumab or any of the excipients